title: Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma.
abstract: The purpose of this study was to assess the results of allogeneic stem cell transplantation (allo-SCT) after reduced-intensity conditioning (RIC) from matched related donors (MRD) and unrelated donors (URD) in 40 patients with high-risk multiple myeloma (MM) in a single centre. Seventeen (43%) (Group 1) and 23 patients (57%) (Group 2) had URD and MRD, respectively. Thirty-nine patients (98%) received one or more autologous transplantation. The median follow-up was 22 months (1-49). None of our patient experienced a graft rejection. The cumulative incidence of grade II-IV acute GVHD was higher (47%) for the URD vs. (17%) for the MRD (P = 0.092). The cumulative incidence of chronic GVHD was no different between the two groups (24% vs. 30%, respectively). At 2 yr, the TRM probabilities were lower in the unrelated group 12% vs. 22% in the related group (P = 0.4). Also at 2 yrs, for patients receiving unrelated transplantation overall and progression-free survivals, 59% and 42%, respectively compared to patients with related donor transplantation, 66% and 44% (P = 0.241). In conclusion, these results suggest that URD in MM is feasible. The small number of patients with URD emphasizes the need to delineate indications and perform prospective protocols.
authors.affiliation: Unité de Transplantation et de Thérapie Cellulaire (U2T), Institut Paoli-Calmettes, Marseille, France. elcheikhj@marseille.fnclcc.fr
authors.forename: Jean
authors.initials: J
authors.lastname: El-Cheikh
authors.forename: Roberto
authors.initials: R
authors.lastname: Crocchiolo
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Boher
authors.forename: Sabine
authors.initials: S
authors.lastname: Furst
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Stoppa
authors.forename: Patrick
authors.initials: P
authors.lastname: Ladaique
authors.forename: Catherine
authors.initials: C
authors.lastname: Faucher
authors.forename: Boris
authors.initials: B
authors.lastname: Calmels
authors.forename: Luca
authors.initials: L
authors.lastname: Castagna
authors.forename: Claude
authors.initials: C
authors.lastname: Lemarie
authors.forename: Jean-Marc Schiano
authors.initials: JM
authors.lastname: De Colella
authors.forename: Diane
authors.initials: D
authors.lastname: Coso
authors.forename: Reda
authors.initials: R
authors.lastname: Bouabdallah
authors.forename: Christian
authors.initials: C
authors.lastname: Chabannon
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
mesh_terms: D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000401:mortality; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D012189:Retrospective Studies; D012307:Risk Factors; D035781:Siblings; D014019:Tissue Donors; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous